Research progress of the impact of nonalcoholic fatty liver disease on chronic hepatitis B infection

doi:10.3969/j.issn.1674-8115.2023.12.015

Abstract

Abstract:

Chronic hepatitis B (CHB) is an infectious disease caused by persistent infection with the hepatitis B virus (HBV) and is highly prevalent worldwide. Non-alcoholic fatty liver disease (NAFLD) is a group of liver diseases related to metabolic abnormalities, excluding those caused by alcohol consumption or other liver injury factors. In recent years, with improvement of living standards and changes in lifestyle, the incidence of NAFLD has been increasing substantially, becoming the most common type of liver diseases in China and Western countries, and the second leading cause of liver transplantation in the West. The rising prevalence of NAFLD has also led to an increase in the incidence of NAFLD in patients with chronic HBV infection. However, there is considerable controversy both domestically and internationally regarding the relationship between these two diseases, including the disease progression, pathogenesis, impact on antiviral treatment efficacy, and prognosis of these concomitant CHB and NAFLD patients. Currently, both domestic and international guidelines lack detailed descriptions of diagnostic and treatment strategies for these conditions. This article summarizes the recent research progress in concomitant CHB and NAFLD, including epidemiology, diagnostic criteria, the impact of NAFLD on the virology of HBV infection, potential mechanisms of NAFLD-induced negative regulation of HBV, the effect of NAFLD on antiviral therapy efficacy, and prognosis. This article aims to gain a deeper understanding of the diseases themselves and provide new insights for basic and clinical research as well as diagnostic and treatment approaches.

Key words: hepatitis B virus (HBV), chronic hepatitis B (CHB), non-alcoholic fatty liver disease (NAFLD), antiviral therapy, hepatocellular carcinoma

CLC Number:

R575.5

BENEDICK Jun Er Chin, SON Peng, ZHANG Yifan, WANG Junqing, GUO Simin. Research progress of the impact of nonalcoholic fatty liver disease on chronic hepatitis B infection[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(12): 1585-1590.

TrendMD

References 33

1	ESLAM M, SANYAL A J, GEORGE J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1.
2	World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016‒2021: actions for impact. Web annex 1: key data at a glance[EB/OL]. [2023-10-30]. https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.pdf.
3	YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84.
4	SHI Y W, YANG R X, FAN J G. Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion[J]. World J Gastroenterol, 2021, 27(26): 3971-3983.
5	ZHONG G C, WU Y L, HAO F B, et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: a case-control study with propensity score analysis[J]. J Viral Hepat, 2018, 25(7): 842-852.
6	HUANG J, JING M, WANG C, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: a population-based study[J]. J Med Virol, 2020, 92(8): 1191-1197.
7	BACAKSIZ F, GÖKCAN H, AKDOĞAN M, et al. Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients[J]. Int J Clin Pract, 2021, 75(12): e14899.
8	LIU L, LI H, ZHANG Y, et al. Hepatitis B virus infection combined with nonalcoholic fatty liver disease: interaction and prognosis[J]. Heliyon, 2023, 9(1): e13113.
9	HU D, WANG H, WANG H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model[J]. Hepatol Int, 2018, 12(5): 438-446.
10	CEYLAN B, ARSLAN F, BATIREL A, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir[J]. Turk J Gastroenterol, 2016, 27(1): 42-46.
11	郑伟, 潘宏义, 吴青青, 等. 慢性乙型肝炎合并肝脂肪变性患者的临床及病理特征分析[J]. 中华临床感染病杂志, 2019, 12(2): 87-92.
	ZHENG W, PAN H Y, WU Q Q, et al. Analysis of clinical and pathological features of chronic hepatitis B patients with hepatic steatosis[J]. Chinese Journal of Clinical Infectious Diseases, 2019, 12(2): 87-92.
12	ZHANG J, LIN S, JIANG D, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors?[J]. Liver Int, 2020, 40(3): 496-508.
13	HE W, REBELLO O, SAVINO R, et al. TLR4 triggered complex inflammation in human pancreatic islets[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(1): 86-97.
14	RIUS-PÉREZ S, TORRES-CUEVAS I, MILLÁN I, et al. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism[J]. Oxid Med Cell Longev, 2020, 2020: 1452696.
15	PICCININ E, VILLANI G, MOSCHETTA A. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(3): 160-174.
16	SHLOMAI A, PARAN N, SHAUL Y. PGC-1α controls hepatitis B virus through nutritional signals[J]. Proc Natl Acad Sci U S A, 2006, 103(43): 16003-16008.
17	HUI R W H, SETO W K, CHEUNG K S, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study[J]. J Viral Hepat, 2018, 25(1): 97-104.
18	KANDA T, MATSUOKA S, YAMAZAKI M, et al. Apoptosis and non-alcoholic fatty liver diseases[J]. World J Gastroenterol, 2018, 24(25): 2661-2672.
19	ESLAM M, VALENTI L, ROMEO S. Genetics and epigenetics of NAFLD and NASH: clinical impact[J]. J Hepatol, 2018, 68(2): 268-279.
20	ESLAM M, MANGIA A, BERG T, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes[J]. Hepatology, 2016, 64(1): 34-46.
21	KIM D S, JEON M Y, LEE H W, et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir[J]. Clin Mol Hepatol, 2019, 25(3): 283-293.
22	MAK L Y, HUI R W, FUNG J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73(4): 800-806.
23	高红伟, 毛重山, 张淑凤, 等. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病的效果观察[J]. 中国实用医刊, 2020, 47(22): 85-88.
	GAO H W, MAO C S, ZHANG S F, et al. Efficacy of entecavir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease[J]. Chinese Journal of Practical Medicine, 2020, 47(22): 85-88.
24	LI J, RUI F, GARCIA E, et al. Antiviral therapy response in chronic hepatitis B patients with and without fatty liver: a systematic review and meta-analysis[C/OL]. Proceedings of the 32th APASL 2023, Taipei, China, February 15‒19, 2023[2023-10-30]. https://www.apasl2023.tw/#/page/ABSTRACT%20BOOK.
25	MAK L Y, SETO W K, HUI R W, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval[J]. J Viral Hepat, 2019, 26(7): 818-827.
26	SHARIF A, ABBAS Z, AHMED S, et al. Effect of non-alcoholic fatty liver disease on transaminase levels and transient elastography in patients with chronic hepatitis B[J]. Cureus, 2019, 11(10): e5995.
27	HU D, DIAO Y, WANG H, et al. Clinical features and severity of non-obese nonalcoholic fatty liver disease in patients with chronic hepatitis B[C/OL]. Proceedings of the 32th APASL 2023, Taipei, China, February 15‒19, 2023[2023-10-30]. https://www.apasl2023.tw/#/page/ABSTRACT%20BOOK.
28	CHAN A W, WONG G L, CHAN H Y, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2017, 32(3): 667-676.
29	CHO H, CHANG Y, LEE J H, et al. Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B[J]. J Clin Gastroenterol, 2020, 54(7): 633-641.
30	PELEG N, ISSACHAR A, SNEH ARBIB O, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load[J]. JHEP Rep, 2019, 1(1): 9-16.
31	ZHANG N, WANG Y, ZHANG J, et al. N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1[J]. FASEB J, 2020, 34(11): 15338-15363.
32	VINCIGUERRA M, CARROZZINO F, PEYROU M, et al. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN[J]. J Hepatol, 2009, 50(6): 1132-1141.
33	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15(6): 401-427.
	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. Chinese Journal of Clinical Infectious Diseases, 2022, 15(6): 401-427.

[1]	LI Qianyu, GUO Wenyun, QIAN Yifei, LI Songling, ZHU Zijun, LIU Yanfeng. Study on the significance and mechanism of ASGR1 in hepatocellular carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1107-1114.
[2]	YU Li, SU Xiandu, ZHANG Min, LI Yahui, WANG Le. Construction and validation of prognostic risk model for hepatocellular carcinoma based on biological analysis of palmitoyl-associated enzyme long-chain non-coding RNA [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(6): 747-754.
[3]	LIU Junjun, LU Sumei, ZHANG Bingyang, LI Yongqing, MA Wanshan. Analysis of m⁶A methylation expression profiles in liver tissue of high-fat diet-induced mouse models of NAFLD [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1227-1235.
[4]	LU Yu, WANG Hao, BA Qian. Role of gut microbiota in hepatocellular carcinoma: cancer occurrence, progresses and treatments [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 939-944.
[5]	HU Zhexuan, ZHANG Xin, WO Lulu, LI Jingchi, WANG Jiao, ZHOU Cixiang, ZHAO Qian. Study on the function of TRMT61A in liver cancer cell and its mechanism [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(6): 742-750.
[6]	Xiaowen ZHANG, Yi WANG, Chan ZHANG, Di ZHANG, Hang YUN, Di HUANG. Effects of Pcsk9 gene interference on high fat-induced nonalcoholic fatty liver disease with atherosclerosis in rats [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 150-157.
[7]	Yihuan WANG, Ruokun LI, Huanhuan CHONG, Fuhua YAN. Research progress of Gd-EOB-DTPA-enhanced magnetic resonance imaging in the evaluation of biological behavior of hepatocellular carcinoma [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 130-134.
[8]	Chao SANG, Dan-dan LIANG, Guo-xiang XIE, Wei JIA, Tian-lu CHEN. Progress in serological noninvasive diagnostic methods for non-alcoholic fatty liver disease [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 112-117.
[9]	HUANG Jin-guo1, ZHANG Hai-nan1, CHEN Zi-qing1*, YANG Li-na2, GUO Shu-juan1, TAO Sheng-ce1. Metabolomics study of the effect of arsenic trioxide on hepatocellular carcinoma cell line HepG2 [J]. , 2018, 38(10): 1145-.
[10]	YING Chen1, LIU Cai-hong2, HU Jia-an2, JIANG Shi-hu3, XU Zhi-hong2, SUN Jing2. Research on level of serum lipid metabolism related hormones in patients of obstructive sleep apnoea hypoxia syndrome combine with non-alcoholic fatty liver disease [J]. , 2018, 38(10): 1203-.
[11]	HAN Ke-qi, RUAN Xin, HE Ming. Roles of SIRT2 in the tumorigenesis and development of hepatocellular carcinoma [J]. , 2018, 38(10): 1247-.
[12]	LI Yong-ning, XIONG Xiao-jing,LI Qing-song, LIU Ying, HU Zheng, CAO Wen-wu. Study on the mechanism of in vitro apoptosis induced with 5-aminolevulinic acid-mediated sonodynamic therapy in Hep G2 cells [J]. , 2016, 36(5): 648-.
[13]	LUO Cui-song, LIN Yun, ZOU Wei-bing, SHI Jun. Clinicopathologic characteristics and prognostic factors for hepatocellular carcinoma patients with diabetes mellitus [J]. , 2016, 36(12): 1736-.
[14]	CHEN Mo, ZHAO Kun, LIU Peng-cheng, WANG Gen-nian, WEI Feng-xian, NI Rui, XU Xiao-dong, ZHANG You-cheng . Effects of silencing GP73 with siRNA interference on the migration and invasion of human hepatoma HepG2 cells [J]. , 2016, 36(11): 1588-.
[15]	XU Yi-Wei, SUN Han-dong, HUANG Ying. Effects of autophagy on adenanthin-induced death of human hepatocellular carcinoma Bel-7402 cells [J]. , 2015, 35(8): 1130-.